The potential role of new drugs in reducing expenditures for non-drug health services has received considerable attention in recent policy debates. We estimate expenditure models to determine whether the use of newer drugs to treat cardiovascular conditions is associated with lower (or higher) non-drug expenditures for these conditions. We fail to substantiate the findings of previous research that newer drugs are associated with reductions in non-drug expenditures. We find, however, that increases in the number of drugs used, or the mix of drugs of different ages, are associated with increased non-drug expenditures and find that the number or mix of drugs used are important confounders in the estimated association between drug age and non-drug expenditures.
Spending on prescription drugs in the United
States rose rapidly in the late 1990s, increasing by more than 15% per year for three consecutive years (Levit et al. 2002) . Several recent studies have focused on the role of new drugs in these increased expenditures (Merlis 2000) . New, patented brand-name drugs typically have higher prices than older drugs, but also are advertised to have new or improved treatment advantages over older drugs. With the increased access to and use of new drugs, the potential role of new drugs in reducing expenditures for inpatient hospital stays and other non-drug health services has received considerable attention in recent health policy debates (Lichtenberg 2001 (Lichtenberg , 2002 . Information on whether the use of new drugs generates cost savings on non-drug health expenditures is critical to policymakers as they evaluate the potential costs of new programs. For example, the net cost of the drug benefit in the recently passed Medicare Modernization Act will depend, in part, on whether increased purchases of new drugswhich may be induced by expanded drug coverage-will be effective in reducing non-drug expenditures.
In this paper, we use nationally representative data on health care expenditures to investigate the role of prescription drugs in treating cardiovascular conditions. In the 1990s, a number of new cardiovascular drugs were introduced in the U.S. market and quickly became top-selling drugs. A number of older drugs also continued to play a prominent role in the treatment of cardiovascular conditions in the 1990s. 1 We employ this variation in the age of drugs to determine whether the use of new drugs to treat cardiovascular conditions is associated with lower (or higher) per person non-drug health expenditures for these conditions. In separate model specifications, we control for two types of confounding variables: the number of drugs used and the mix of drugs of different ages. We find that the number of drugs used is an important confounding factor because it is correlated with both our measure of drug age and with non-drug health expenditures. We find similar results in models that employ the standard deviation of the age of drugs used by an individual to control for the mix of drugs that each person purchases. Our models are designed to estimate the association between non-drug expenditures and drug age while controlling for a wide range of observable characteristics. We do not attempt to determine a causal relation between these variables. Unobserved differences across individuals may affect choices regarding the age, quantity, and mix of drugs purchased, and this may have important implications for our estimates. For example, differences in the severity of illness that are not fully captured by our condition or health status variables may affect our measure of drug age, the number and mix of drugs used, and non-drug expenditures. Also, the Medical Expenditure Panel Survey (MEPS) data that we use measure annual non-drug expenditures and annual drug use. This further complicates the task of estimating causal relationships because with annualized data we are not able to determine whether drug use precedes, or follows, other health service expenditures within the year. Instrumental variables provide a potential method of correcting for endogeneity, but such estimation techniques also may prove to be worse than the approach we have adopted in our study (Bound, Jaeger and Baker 1993; Staiger and Stock 1993) . Our estimates do provide, however, information on adjusted patterns of health care service use in the treatment of cardiovascular conditions.
Background
Much of the interest in the association between drug age and non-drug expenditures stems from two recent papers by Frank Lichtenberg (2001 Lichtenberg ( , 2002 in which he uses nationally representative data from the Medical Expenditure Panel Survey to test the hypothesis that ''new drugs within a class or for a given diagnosis are of higher quality than older drugs.'' Lichtenberg's models use person-condition level data and include condition fixed effects so coefficients are identified by within-condition variation in drug age and nondrug expenditures. He finds qualitatively similar results in models in the 2001 paper that control for observable individual characteristics, and models in both 2001 and 2002 that include dummy variables for each individual. Lichtenberg finds that the use of newer drugs reduces non-drug expenditures 3.9 to 7.2 times as much as it increases drug expenditures. A majority of the savings (62% to 89%) are estimated to be due to reductions in inpatient hospital expenditures. Lichtenberg also finds reductions in morbidity and mortality associated with the use of new drugs and concludes that newer drugs are higher in quality and are ''worth the cost.''
The evidence from other studies on the association between drug and non-drug expenditures is mixed.
2 A large literature focuses on the cost effectiveness of specific drugs that are formulated to treat specific health conditions. Neumann et al. (2000) review cost-effectiveness studies that present results in terms of cost-per-qualityadjusted life year. They find that some drugs are cost saving (they reduce the overall cost of treatment), some are cost effective (they increase overall costs, but produce outcomes that are worth the cost), and some drugs are neither cost saving nor cost effective. They also note that the effectiveness of any drug depends critically on the context in which the drug is used and on the intervention with which it is compared, making an extrapolation from studies of individual drugs to the general population very difficult.
Other researchers have investigated the impact of drug use on non-drug expenditures by examining changes in state Medicaid policies that alter recipients' access to drugs. In 1981, for example, the New Hampshire legislature limited Medicaid reimbursement to three prescriptions per month as a cost-saving measure. Soumerai et al. (1994) investigate the impact of the threeprescription limit on Medicaid recipients with schizophrenia and find that the resulting increase in non-drug expenditures was much larger than the reduction in drug expenditures. 3 In another study of the treatment of schizophrenia in the Medicaid population, Duggan (2005) investi-gates the impact of shifting recipients from older to newer antipsychotic drugs. He finds that use of newer drugs did not reduce hospital or long-term care use and, in fact, caused an overall increase in government spending.
While the continuing advance of medical knowledge suggests the potential for newer drugs to provide increased value relative to older drugs, other factors may reduce the ability of newer drugs to fully deliver on this potential (Garattini and Bertele 2004) . For example, the regulatory process for drug approval does not require a new drug to demonstrate superiority to existing drugs, but rather to demonstrate efficacy relative to a placebo. Past research has presented mixed information on the ability of newer cardiovascular medications to provide increased value relative to older drugs. A large recent clinical trial demonstrated that users of a newer statin, Lipitor (atorvastatin calcium), which was approved in 1996, had lower rates of heart attacks and other adverse cardiovascular events than users of an older statin, Pravachol (pravastatin sodium), which was approved in 1991 (Kolata 2004) . The treatment of hypertension provides a counter example as published meta-analyses (Psaty et al. 2003 ) and large clinical trials (ALLHAT 2002) fail to show the superiority of newer medications when compared to treatment with the much older thiazide diuretics.
Finally, studies by Moeller et al. (2003) and Wouters (1991) show that current drug expenditures are strong predictors of future non-drug expenditures. Moeller et al. (2003) find that the number of drug purchases in the first half of the year was among the best predictors of which people would have high medical expenditures in the second half of the year. Wouters (1991) investigates the predictive power of disaggregated health expenditures in year one for year two total and disaggregated expenditures. She finds that outpatient drug expenditures were the strongest predictor of any disaggregated service. The approach of these studies differs from that of others like Soumerai et al. (1994) in that their goal is to predict expenditures based on observable characteristics, not to examine the impact of exogenous changes in drug use. The strong positive relationship between drug quantity and non-drug expenditures that both Moeller et al. (2003) and Wouters (1991) find, therefore, could be largely driven by unobservable characteristics that are correlated with drug use. For example, characteristics of the physician or differences in the severity of illness, which are not fully captured by condition or health status variables, may affect both the quantity and mix of drugs used and non-drug expenditures.
Data and Methods
This study uses data from the Medical Expenditure Panel Survey Household Component (MEPS-HC) for the years 1996 through 1999. The MEPS, which is sponsored by the Agency for Healthcare Research and Quality (AHRQ), yields nationally representative estimates of health care utilization, expenditures, and conditions. 4 We use the MEPS data to estimate the association between the age of drugs used to treat cardiovascular conditions and the non-drug expenditures for the same conditions. The sample for this study is limited to people at least 35 years old, and who reported at least one cardiovascular condition 5 during the year. Overall our sample includes observations for an unweighted total of 16,606 person-years for people who reported at least one cardiovascular condition during the year. Within this sample, an unweighted total of 14,303 person-year observations are for people who purchased at least one drug to treat their cardiovascular conditions. An unweighted total of 167,487 prescriptions were purchased to treat these conditions.
In separate models, we test the sensitivity of the association between drug age and non-drug expenditures to the exclusion or inclusion of controls for the number of drugs used and the mix of drugs used of different ages to treat cardiovascular conditions. The first set of models that we estimate can be characterized by the following equation: expenditure ist ¼ f ðdrug age it ; number of drugs used it ; condition it ; comorbidity it ; X it ; Year t Þ where expenditure ist is the expenditure to treat cardiovascular conditions by person i for service s (s ¼ ambulatory, inpatient hospital, home health, total non-drug, prescription drug, total) in year t. In our models we follow the approach in Lichtenberg (2001 Lichtenberg ( , 2002 and estimate ordinary least squares (OLS) models of the associa-tion between drug age and non-drug expenditures for all people, regardless of whether they had positive expenditures for a given service. In a second set of models, we replace the number of drugs used by each individual with the standard deviation of the age of drugs purchased by each individual.
The primary variable of interest in our models, drug age, is calculated at the level of the individual drug purchase as drug age ¼ 1999 -the year of approval by the Food and Drug Administration (FDA), and ranges from 0 to 60. We determined the approval year for each drug by using the active ingredient(s) to link each drug to the FDA new drug applications list. The drug age distribution is truncated at 60 because the modern era of FDA drug approvals did not begin until 1939. Following Lichtenberg (2002) , we summarize drug use at the person-level using average drug age and specify drug age as ln (average drug age) in our models.
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The other variables of interest in our models are the number and mix of drugs used. The number of drugs used is the number of unique drugs (active ingredients) that people used to treat their cardiovascular conditions. We believe that the number of drugs used provides an important proxy measure for differences in the severity of illness that are not fully captured by other condition or health status variables. The standard deviation of drug age provides information on the mix of drugs used. As we document subsequently, our measure of drug age is highly correlated with both the number of drugs and the mix of drugs that each person uses. To obtain unbiased estimates of the association of drug age with nondrug expenditures, therefore, we must control for these potentially confounding variables.
A central component of our estimation strategy is the inclusion of a set of dummy variables (condition it ) for cardiovascular conditions. Each person-year observation in our data includes expenditures and dummy variables for one, or more, cardiovascular conditions. Reported cardiovascular conditions include highly prevalent conditions such as hypertension and hyperlipidemia as well as less prevalent, but more serious, conditions such as acute myocardial infarctions and heart failure (see Table 1 for a list of common conditions).
7 Inclusion of these dummy variables is essential as both drug age and non-drug expenditures vary substantially across conditions. Our models also include a set of dummy variables (comorbidity it ) that indicate the number of noncardiovascular chronic conditions that each person reported and an extensive set of person-level control variables (X it ). Means for these variables are also presented in Table 1 . The ''year'' variable in the expenditure equation represents a set of dummy variables indicating the specific year (1996) (1997) (1998) (1999) of the sample data.
In contrast to our approach, Lichtenberg (2002) uses person-condition level data (i.e., an individual's hypertension, hyperlipidemia, and heart attack are separate observations) and includes fixed effects for all conditions. Estimates, therefore, are identified by within-condition (3-digit ICD9) variation in drug age and non-drug expenditures. Since there are potential relationships between specific cardiovascular conditions (i.e., a heart attack may be caused by inadequate treatment of hypertension), this ''within-group'' approach may be overly restrictive. Our personlevel models allow for these types of inter-relationship across all cardiovascular conditions. To test the sensitivity of results to alternative specifications, however, we also estimated personcondition level models using data for the 13 most frequently reported cardiovascular conditions (see Table 1 for a list of these conditions).
A second important difference between our study and both Lichtenberg (2001 Lichtenberg ( , 2002 studies is that his use data for all conditions, so that the estimated relationship between drug age and nondrug expenditures represents the average relationship across all reported conditions. 8 In our study, the data are limited to a narrower, more homogenous set of conditions-cardiovascular conditions. By limiting our data, we focus on one economically important group of conditions for which drugs play a well-defined role in the primary and secondary prevention of hospitalization.
Descriptive Results
Table 2 presents information on aggregate and per capita expenditures for health services used to treat cardiovascular conditions and the total amount spent by people with cardiovascular conditions. From 1996 to 1999, people age 35 and older who reported at least one cardiovascular condition spent $104.5 billion (in 1999 dollars) each year to treat those conditions. These expenditures accounted for about 40% of the $259.2 billion in total health expenditures by this group. The mean expense per person to treat cardiovascular conditions was $2,289, and the mean per person with an expense was $2,458. Prescription drugs accounted for 19.1% of expenditures for cardiovascular conditions with non-drug expenditures accounting for the remaining 80.9% of expenditures. 9 Inpatient hospital expenditures, the largest component of non-drug spending, accounted for more than half (56.6%) of all expenditures for cardiovascular conditions. Drugs were the most widely utilized service, with 85.2% of people using at least one drug to treat their cardiovascular conditions. People who used drugs had an average of 11.8 prescriptions and 2.3 unique drugs annually (not shown).
10 As expected, newer drugs were much more expensive, on average, than older drugs. For example, the average prescription price (in 1999 dollars) for drugs approved by the FDA after 1992 was $67.03, more than three times the average price of $21.02 for drugs approved before 1950 and more than twice the average price for drugs approved between 1968 and 1980 ( Figure 1 ).
Drug Age and the Number and Mix of Drugs Used
Many individuals use more than one drug to treat their cardiovascular conditions and we find that people who purchase multiple drugs tend to purchase drugs with a mix of ages. For example, Figure 2 shows that, on average, people who used two different drugs during the year purchased drugs that were approved by the FDA in an average of 1.8 different decades, while people who used five drugs purchased drugs from an average of 3.5 different decades, and people who used nine drugs purchased drugs that were approved in five different decades.
11 These patterns of use are indicative of a high degree of dispersion in individuals' drug purchases across the six decades of drug approval dates. These patterns also suggest that individuals do not systematically choose old or new drugs, which significantly complicates the task of estimating the association between drug age and non-drug expenditures.
To estimate this association, we follow Lichtenberg (2002) in using average drug age to summarize drug use at the person level. Testing the hypothesis that newer drugs are associated with lower non-drug costs involves disentangling the effect of average drug age from the effect of the number and mix of unique drugs used. The top line in Figure 3 shows that people who purchased drugs with an average age in the middle of the distribution (average age 25 to 31 years) bought an average of 3.7 drugs, more than any other group shown in the figure. This occurs because people who buy multiple drugs tend to buy an assortment of old and new drugs whose average age is in the middle of the distribution. People who purchase only one drug, on the other hand, may choose a drug of any age, but they are more likely than those with multiple purchases to be found in the tails of the average drug age distribution. As Figure 3 illustrates, people in the tails of the average drug age distribution purchased the fewest drugs, with those in the ''49 or more'' and ''less than 7'' groups purchasing an average of 1.6 and 1.3 drugs, respectively.
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The two lower lines in Figure 3 separately plot the average number of new drugs and the average number of old drugs purchased by people in each average drug age category. (For each person, the number of old drugs plus the number of new drugs is equal to the total number of drugs used.) In this figure, new drugs are defined as drugs that are 18 years old or newer. We chose this cutoff because 18 years is the median drug age in the MEPS data, and it closely approximates the time that a drug normally would remain on patent. Figure 3 illustrates that on average there were purchases of both new and old drugs by people in every average drug age category. It also shows that people in the middle of the drug age distribution (average age between 25 and 31 years) and people in the newest drug age category (average age less than seven years) both purchased an average of about 1.6 new drugs per year. The difference in drug use between these two groups was that people in the ''25 to 31'' category also purchased an average of 2.1 old drugs.
The standard deviation of the age of drugs used also varies across the drug age distribution as individuals purchase different mixes of drugs. The standard deviation of drug age is the highest for people in the ''25 to 31'' drug age category (15.2) because on average they purchase the greatest mix of new (1.6) and old (2.1) drugs. The standard deviation declines steadily to .6 and 4.0 as the average drug age approaches the newest (''less than 7'') and oldest (''49 or more'') drug age categories, respectively (not shown). In the ''49 or more'' drug age category, the mean numbers of new and old drugs purchased are .06 and 1.6, respectively, while in the ''less than 7'' drug age category the respective means are 1.3 and .01. Figure 4 shows that a strong positive relationship exists between the number of drugs used and a major determinant of non-drug spending, the probability of an inpatient hospital stay. The percentage of people with an inpatient stay ranges from a low of 2.8% for those who purchased one drug, to 54.3% for those who purchased nine or more drugs. The relationships between the number of drugs used and other components of non-drug spending, including total non-drug expenditures, are qualitatively similar. Figure 5 presents the relationship between average drug age and the percentage of people with an inpatient stay and shows that those in the middle of the drug age distribution (average drug age 25 to 31 years) are about seven times more likely to be hospitalized (15.1% vs. 2.2%) than people in the newest drug age category (average drug age less than seven years). As noted earlier, both groups used an average of 1.6 new drugs, but the ''25 to 31'' group also purchased an average of 2.1 old drugs, possibly indicating that they were more seriously ill, on average, than the ''less than 7'' group.
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The univariate results presented in this section demonstrate that a relationship exists between the average age of drugs used and both the number and mix of drugs used. Our univariate results, and previous research, also suggest that there is a strong association between the number of drugs used and non-drug expenditures, and that failure to control for the number or mix of drugs used may result in biased estimates of the association between average drug age and non-drug expenditures. In the next section, we examine this issue further by estimating multivariate models of this association.
Regression Results

Person-Level Models
In this section, we present results from multivariate models that estimate the association of nondrug expenditures to treat cardiovascular conditions with the average age and the number and mix of drugs used to treat the same conditions. We follow Lichtenberg (2002) in estimating OLS models for all people, regardless of whether they had positive expenditures for a given service, and in specifying drug age as ln(average drug age). The six panels in Table 3 present results for models that use ambulatory, inpatient hospital, home health, total non-drug, prescription drug, The model 1 results, which do not control for the number or mix of drugs used, are qualitatively similar to Lichtenberg's findings. In particular, decreasing the average age of drugs by one log unit (i.e., from 41 to 15, or from 15 to 5.5) is associated with a $68.23 increase in drug expenditures, a $44.38 reduction in ambulatory expenditures, and a $208.88 decrease in total non-drug expenditures. Each additional dollar of spending on new drugs, therefore, is associated with a $3.06 (3.06 ¼ 208.88/68.23) reduction in nondrug health expenditures.
14 Although the coefficient in the inpatient model is not statistically significant, the point estimate of $137.00 suggests that reductions in inpatient spending account for the majority (66.6%) of the estimated savings on non-drug expenditures.
The model 2 results show that when we control for drug quantity by adding ln(number of drugs) to the model the results change dramatically. The most important change is that a reduction in drug age is no longer associated with a reduction in non-drug spending. The drug age coefficients in three of the four models for non-drug services change sign (suggesting an increase in nondrug expenditures as drug age falls) but are statistically insignificant. We also find that decreasing the average age of drugs by one log unit is now associated with a much larger increase in drug expenditures of $157.49, and is also associated with an increase in total expenditures of $293.37. In models that control for the number of drugs, therefore, use of newer drugs, on average, is associated with an increase in total expenditures.
In model 3, we substitute drug mix as measured by the standard deviation of drug age for ln(number of drugs). Controlling for drug mix we find no statistically significant associations between drug age and non-drug expenditures. Similar to the results for model 2, we find that a one log unit reduction in drug age is associated with an increase in prescription drug expenditures of $142.75 and an increase in total expenditures of $203.12.
The change in the direction of the associations between average drug age and non-drug expendi- tures from model 1 to models 2 or 3 suggests that estimates in model 1 are biased and are dominated by the omitted drug quantity or drug mix variables and perhaps by other omitted variables. Models 2 and 3 provide additional evidence for this hypothesis. These models show that, controlling for either the number of drugs or a measure of drug age mix, all estimated associations between the various categories of non-drug spending and average drug age are statistically insignificant. By contrast, the coefficients on ln(number of drugs) and the standard deviation of drug age are highly significant in these models except for the home health equations. The coefficients show that using more drugs and using a greater mix of drugs are both associated with significantly higher non-drug expenditures. Table 4 reports results for person-condition level models that were estimated using data for the 13 most common cardiovascular conditions (see Table 1 for a list of these conditions). In examining plots of the data, we found that, for most conditions, the relationship between drug age and the number of drugs used was qualitatively similar to the relationship illustrated in Figure 3 (not shown). Further, when we estimated multivariate person-condition level models we found results that were qualitatively similar to those reported in models 1, 2 and 3 in Table 3 . Most importantly, results for model 1 in Table 4 show that when we do not control for the number or mix of drugs, a one log unit reduction in drug age is associated with a $144.30 decrease in total non-drug spending and a $70.12 increase in drug spending. Each additional dollar spent for new drugs, therefore, is associated with a $2.06 ($2.06¼ $144.30/$70.12) reduction in non-drug spending. When variables for either the number or mix of drugs are added in models 2 and 3 of Table 4 , however, the association between drug age and total non-drug expenditures is negative and statistically insignificant.
Person-Condition Level Models
Other Model Specification Issues
As noted previously, a central component of our estimation strategy is to include dummy variables for cardiovascular conditions that are recorded at the 3-digit ICD9 level. Since substantial heterogeneity may exist within these conditions, we also chose to include variables intended to measure the severity of individuals' conditions. These include health status variables, disability and limitations variables, and indicators of death and institutionalization. Contemporaneous measures of health status, however, can be potentially endogenous variables in models of non-drug expenditures, drug age, and drug quantity.
As a further test of the robustness of our results, therefore, we dropped these health status measures and re-estimated the models in Tables  3 and 4 . For the models that do not control for the number or mix of drugs (model 1), we found that the magnitude of the drug age coefficient generally increased. For example, in models without health or limitation variables, a one-log unit decrease in average drug age was associated with a $309.46 ( p , .05) reduction in total non-drug spending in the person-level models, and a $188.99 ( p , .05) reduction in non-drug spending in the person-condition level model (not shown). This compares to reductions in non drug spending of $208.88 in the person-level model (Table 3 ) and $144.30 in the person-condition level model (Table 4 ) when health and limitation variables are included. Adding controls for the number or mix of drugs used in these models, however, continued to either reverse the signs on the drug age coefficients and/or make them statistically insignificant. Finally, we re-estimated the models in Tables  3 and 4 as fixed-effects models. In addition to our measures of drug age, number of drugs, and mix of drugs, these models included individual fixed effects, condition dummies, and year dummies. For the person-level models, use of fixed effects did not qualitatively alter our results (not shown). In the person-condition level fixedeffects models, results for models that controlled for the number or mix of drugs were also qualitatively similar to those reported in Table 4 . In models that excluded these controls, however, we did not find a statistically significant association between drug age and total non-drug expenditures (not shown), a finding in contrast to the results presented in Table 4 .
Conclusion
In this paper, we use nationally representative MEPS data to estimate expenditure models by type of service (inpatient, ambulatory, home health, total non-drug) to determine whether the use of newer drugs to treat cardiovascular conditions is associated with lower (or higher) nondrug health expenditures for these conditions. We test the sensitivity of results to the exclusion or inclusion of two important confounding variables: the number of drugs, and the mix of drugs purchased by an individual. Our models control for a wide range of observable characteristics, but we do not attempt to correct our estimates for the potential endogeneity of drug choice. Our estimates, therefore, provide information on adjusted patterns of health care services used to treat cardiovascular conditions in the U.S. noninstitutionalized population. When we follow Lichtenberg (2002) in estimating models that specify drug age as ln(average drug age) and do not control for the number or mix of drugs used, we find results that are qualitatively similar to results in that paper. In particular, these models show that the use of newer drugs is associated with reductions in non-drug expenditures. However, when we control for either the number or mix of drugs, the association between non-drug spending and drug age per constant quantity or mix of drugs purchased is statistically insignificant.
Our results, therefore, appear to contradict results in Lichtenberg (2002) . There are important caveats to this conclusion, however, in terms of the scope and level of our analyses. First, Lichtenberg estimates models for all conditions combined, while we focus on cardiovascular conditions. However, cardiovascular conditions are a leading source of both drug and non-drug expenditures, and new drugs used in their treatment have been heavily marketed as superior to older alternatives. Second, Lichtenberg uses personcondition level expenditures, while the primary focus of our analysis is person-level expenditures. We did find, however, that when we reestimated our models at the person-condition level, the addition of variables for the number, or mix, of drugs used had similar effects on the drug age coefficient. Regardless of the scope or level of the analysis, the potential endogeneity of drug choice and the difficulty of disentangling the effects of its components such as average drug age from the number and mix of drugs used present major challenges for this research. Like Moeller et al. (2003) and Wouters (1991) , we find a strong association between the quantity of drugs used and non-drug expenditures. We also find a strong association between the mix of drugs used and nondrug expenditures. Since we do not correct our estimates for the potential endogeneity of drug choice, however, it is plausible that these results are largely driven by unobserved differences across individuals and their physicians. For example, differences in the severity of illness that are not fully captured by our condition or health status variables may affect both the number and mix of drugs used and non-drug expenditures.
Further, because our data are non-experimental, individuals' expenditures are a function, in most cases, of a mix of unique drugs from multiple age periods. Although our models control for quantity and mix, the lack of independence among our drug age, drug quantity, and drug mix variables is a limitation. Demonstrating the sensitivity of the association between drug age and non-drug expenditures to the exclusion, or inclusion, of our quantity and mix variables is important; however, it falls far short of the ideal experimental situation in which the impact of drug age, drug quantity, and drug mix could be independently evaluated. Our research suggests that drug age is one part of an interconnected drug choice variable that includes the number of unique drugs and mix of drugs by age, and is some function of patient age, health status, health insurance coverage, comorbidities, physician prescribing practice, access to care, and other related factors. Isolating the drug age/non-drug expenditure relationship with retrospective data such as the MEPS, therefore, is very difficult.
In addition to these issues, there are several other important limitations of our study. First, because our study uses concurrent data on annual expenditures we do not disentangle important issues of timing (i.e., whether drugs were used before or after the hospitalization) nor do we observe individuals for a long enough period of time to gauge the potential long-run effects of variations in drug use on non-drug health expenditures. The effect of many of the drugs in our study, including antihypertensives and anti-hyperlipidemics, may be realized only after a number of years. Second, our study focuses only on expenditures; it does not investigate potential changes in outcomes that may be associated with the use of old versus new drugs. Our study, therefore, provides information on the potential for drugs to produce cost savings, but does not provide information on the potential cost effectiveness of new drugs. Third, our models estimate drug and non-drug expenditures among people who used drugs to treat their cardiovascular conditions. We do not model individuals' decisions to use drugs to treat their cardiovascular condition(s), nor do we estimate the impact of this decision on non-drug expenditures. This is particularly important for conditions such as hy-perlipidemia, where the availability of new drugs may expand the number of people treated for the condition.
In spite of these limitations, we believe that our study is very relevant to the current policy debate regarding the role of prescription drugs in the production of health. Our study suggests that Lichtenberg's widely cited results-noting that, on average, new drugs generate large cost savings in the context of annual health expenditures-may be sensitive to the inclusion of controls for drug quantity and mix and, more generally, to the failure to isolate the role of drug age apart from its connection to a number of other influences on the drug choice variable.
In our models that include either drug quantity or drug mix, we do not find evidence that new drugs produce cost offsets in the context of annual health expenditures for cardiovascular conditions. There may be specific instances where newer drug therapies outperform older drugs by reducing non-drug expenses in treating specific cardiovascular conditions. There also may be specific instances in which older drugs outperform newer drugs by the same standard. Patients and physicians, often facilitated by pharmaceutical marketing, frequently assume that newer medications are inherently superior to older medications (Ma et al. 2003) . However, the regulatory process for drug approval does not require superiority ;to existing medications, but rather is judged by evidence of efficacy in comparison to placebo. By approaching this question on a macro level, we fail to find evidence that, on average, newer drugs produce cost savings per constant drug quantity or per constant drug mix chosen compared to older drugs in treating cardiovascular conditions. Our study, therefore, provides important information for public and private insurers and others who have annual budgets to provide health care to covered individuals.
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1 Twenty of the top 50 drugs (by expenditure) that were used to treat cardiovascular conditions in the United States from 1996 to 1999 were approved by the FDA during the 1990s. Fifteen of the top 50 drugs (by prescriptions) were approved by the FDA before 1970. 2 For a review see Miller and Moeller (2002) and CBO (2002) . 3 See also Soumerai et al. (1991) , Kozma, Reeder, and Lingle (1990) and Smalley et al. (1995) . 4 For more information on MEPS see Cohen (1997) . 5 Cardiovascular conditions were primarily identified using the conditions ICD9 390 to 450, which are categorized as ''Diseases of the Circulatory System'' in the Code Book for Physician Payment (St. Anthony's 1998). Also included were related conditions such as hyperlipidemia, and fluid and electrolyte disorders for which cardiovascular drugs, coagulation modifiers, or antihyperlipidemic drugs were frequently prescribed. 6 Lichtenberg (2002 Lichtenberg ( , 2001 ) use similar modeling approaches except that the unit of analysis in the 2002 paper is at the person-condition level, while the unit of analysis in the 2001 paper is the prescribed medicine event (drug purchase). In the event-level analysis, there is no need to summarize drug purchases at the person level. On the other hand, the event-level analysis is problematic because person-condition level non-drug expenditures are merged with event-level drug information. This causes several problems. First, the data are, in effect, re-weighted using the number of prescriptions as a frequency weight, so results are not nationally representative. Second, identical observations are repeated multiple times so standard errors have a downward bias. Third, in calculating the savings generated by new drugs, changes in person-condition level non-drug expenditures are compared with changes in the price of a single prescription. Since most conditions are treated with multiple prescriptions, this comparison is inappropriate. 7 In our final models, we included dummies for all cardiovascular conditions that had n 15 person years. Alternative specifications, however, (i.e., n 50 person years; n 1 person year) did not qualitatively alter the results. 8 In Lichtenberg (2001) , he estimates models for individual conditions (defined at the three-digit ICD9 level) with mixed results. 9 Drug expenditures are outpatient drug expenditures only. In the MEPS, expenditures for drugs administered in the hospital are recorded as part of inpatient expenditures. 10 Prescriptions have not been standardized by dosage amounts. Information is available in MEPS on the brand name, quantity, form, strength, and active ingredients of each prescription, but average daily dosage data would be needed for the standardization. 11 People using only one drug necessarily purchase a drug from only one vintage decade. They may, however, purchase a drug of any age (i.e., person A may purchase one drug which was approved in 1991, while person B may purchase one drug approved in 1951). 12 The relationship between drug age and the number of drugs used also exists for other measures of drug age. For example, when we summarize drug age at the person level using the newest drug purchased, we find that people who purchased at least one new drug (less than 7 years old) purchased more drugs (an average of 3.1) than any other group. This occurs because people who buy a larger number of drugs are more likely to buy at least one new drug.
At the other end of the newest drug age distribution, we find that people who purchased only the oldest drugs (49 or more years old) purchased the fewest drugs, an average of 1.1 per person. Therefore, using a newest drug specification also would require that we disentangle the effects of drug age and the number of drugs used. 13 In spite of the small number of drugs purchased, the high rate of hospitalization for people in the oldest average drug age category (49 or more years old) is not unexpected. We find that the average age of drugs used is higher for a number of very serious, less prevalent conditions (e.g., acute myocardial infarction, heart failure, and angina) than for less serious, more prevalent conditions (e.g., hypertension, hyperlipidemia). It is likely, therefore, that people in this group are being treated for serious conditions. 14 Following Lichtenberg (2001 Lichtenberg ( , 2002 , we use coefficient estimates from separate regressions (i.e., the total non-drug model and the drug model) to estimate the savings on non-drug expenditures for each extra dollar spent on new drugs. It is important to note, however, that in the column 1 model where we estimate the association between drug age and total expenditures (total expenditures ¼ total non-drug þ drug), the coefficient on drug age is statistically insignificant.
